Taletrectinib for advanced ROS1-positive lung cancer after entrectinib
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests the drug taletrectinib in people with advanced non-small cell lung cancer that has a specific genetic change called ROS1. It is for those who have already tried the drug entrectinib and their cancer progressed. The study aims to see how well taletrectinib works in the real world.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your lung cancer has spread to other parts of the body (stage 4).
- You have a ROS1 gene fusion, which was found through a special test (FISH, RT-PCR, or NGS).
- You have already been treated with entrectinib, and your cancer got worse after that treatment.
- You have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
This study looks at why the targeted drug entrectinib stops working in some people with ROS1-positive lung cancer. Participants will give blood or tumor samples before and after treatment to help researchers understand resistance.
This study looks at how well a targeted therapy works for people with advanced non-small cell lung cancer that has a specific genetic change called ROS1. It aims to see if this treatment can help control the cancer and improve outcomes.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
This trial tests whether taletrectinib (a targeted pill) can help prevent lung cancer from coming back after surgery in people whose tumors have a ROS1 gene change. You would take either taletrectinib or a placebo (inactive pill) for about a year after surgery.
This trial studies entrectinib, a targeted pill, in people whose cancer has a specific gene change called ROS1 fusion. It may help by shrinking tumors that depend on this ROS1 gene switch, and the study requires starting with a new tissue sample and treatment monitoring.
Hear when a new Non-small Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.